Unable to load global navigation.
Synonyms
- Allopurinol Hypersensitivity
- B58
- B5801
- HLA B*58:01
- HLA B58
Special Instructions
If you have questions, please telephone 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.
Expected Turnaround Time
3 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
Specimen Requirements
Specimen
Whole blood or buccal swabs
Volume
7 mL whole blood or 4 buccal swabs
Minimum Volume
7 mL whole blood or four (4) buccal swabs
Container
Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal kit, please telephone 800-533-1037.
Storage Instructions
Maintain whole blood at room temperature or refrigerate. Keep buccal swabs dry and at room temperature.
Causes for Rejection
Hemolysis; clotted specimen; insufficient volume of DNA
Test Details
Use
Allopurinol associated SCAR (severe cutaneous adverse drug reaction) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) has been shown to be associated with the human leukocyte antigen (HLA) B*58:01 of the major histocompatibility complex (MHC). The MHC family of genes codes for a highly variable set of cell surface glycoproteins (HLAs) that play a critical role in presenting antigens to T-cell receptors to elicit an immune response. The presence of the HLA B*58:01 allele increases the susceptibility to allopurinol SCAR in several populations studied.
Limitations
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for retesting.
Methodology
Sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain the required resolution.
References
Hershfield MS, Callaghan JT, Tassaneeyakul W, et al, Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb, 93(2):153-158.23232549
Hung S, Chung W, Liou L, et al, HLA B*58:01 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. PNAS. 2005 Mar 15;102(11):4134-4139.15743917
Khanna E, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-1446.23024028
Tassaneeyakul W, Jantararoungtong T, Chen P, et al, Strong association between HLA B*58:01 and allopurinol induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009 Sep;19(9):704-709.19696695
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 167351 | HLA B*58:01 | 13299-3 | 167343 | HLA-B | 13299-3 | |
| 167351 | HLA B*58:01 | 13299-3 | 167345 | HLA-B | 13299-3 | |
| 167351 | HLA B*58:01 | 13299-3 | 167384 | HLA Methodology | 49549-9 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf